

CLAIMS AMENDMENTS:

Please cancel claims 60 and 68, without prejudice.

Please amend the claims as follows:

59. (Currently amended) An isolated nucleic acid molecule selected from the group consisting of:

- a) a nucleic acid having the sequence of SEQ ID NO:1;
- b) a nucleic acid molecule having the sequence of SEQ ID NO:3;
- c) a nucleic acid molecule having the sequence of SEQ ID NO:22; and
- d) a nucleic acid ~~sequence~~ molecule that hybridizes under moderate stringency conditions to any one of the nucleic acids of (a), (b), and (c), ~~and~~
- e) ~~— a nucleic acid sequence that encodes an expression product of an amino acid sequence encoded by any of the foregoing nucleic acid sequences.~~

60. (Cancelled)

61. (Currently amended) An isolated nucleic acid molecule that encodes an OB polypeptide capable of modulating body weight; and having one or more polymers attached thereto, said nucleic acid optionally in a pharmaceutical carrier, wherein said OB polypeptide encoded by said isolated nucleic acid comprises the amino acid sequence set out in:

- a) SEQ ID NO:2;
- b) amino acids 22-167 of SEQ ID NO:2;
- c) SEQ ID NO:4 or
- d) amino acids 22-167 of SEQ ID NO:4.

62. (Currently amended) An isolated nucleic acid molecule that encodes an OB

polypeptide capable of modulating body weight; and having one or more polymers attached thereto, said nucleic acid optionally in a pharmaceutical carrier, wherein said OB polypeptide encoded by said isolated nucleic acid comprises the amino acid sequence set out in

- a) SEQ ID NO:5;
- b) amino acids 22-166 of SEQ ID NO:5;
- c) SEQ ID NO:6 or
- d) amino acids 22-166 of SEQ ID NO:6.

63. (Currently amended) An isolated nucleic acid molecule that encodes an OB polypeptide capable of modulating body weight; and having one or more polymers attached thereto, said nucleic acid optionally in a pharmaceutical carrier, wherein said OB polypeptide encoded by said isolated nucleic acid has 83 percent or greater amino acid sequence identity to the OB polypeptide amino acid sequence set out in SEQ ID NO:2, 4, 5 or 6.

64. (Currently amended) An isolated nucleic acid molecule that encodes an OB polypeptide; capable of modulating body weight; and having one or more polymers attached thereto, said nucleic acid optionally in a pharmaceutically acceptable carrier, wherein said OB polypeptide encoded by said isolated nucleic acid is an OB polypeptide variant comprising amino acids 22-167 of SEQ ID NO:4 in which one or more amino acids selected from the group consisting of amino acids 53, 56, 71, 85, 89, 92, 95, 98, 110, 118, 121, 122, 126, 127, 128, 129, 132, 139, 157, 156, 163 and 166, according to the numbering of SEQ ID NO: 4, is substituted with a conserved amino acid.

65. (Currently amended) An isolated nucleic acid molecule that encodes an isolated nucleic acid molecule that encodes an OB polypeptide; capable of modulating body weight; and having one or more polymers attached thereto, said nucleic acid optionally in a pharmaceutically acceptable carrier, wherein said OB polypeptide encoded by said isolated nucleic acid is an OB polypeptide variant comprising amino acids 22-167 of

SEQ ID NO:4 in which one or more of amino acids selected from the group consisting of amino acids 53, 56, 71, 85, 89, 92, 95, 98, 110, 121, 122, 127, 128, 129, 139, 157, 159 and 163, according to the numbering of SEQ ID NO: 4, is substituted with the particular amino acid present at the corresponding position in SEQ ID NO: 2.

66. (Currently amended) An isolated nucleic acid molecule that encodes an OB polypeptide; capable of modulating body weight; and having one or more polymers attached thereto, said nucleic acid optionally in a pharmaceutically acceptable carrier, wherein said OB polypeptide encoded by said isolated nucleic acid is an OB polypeptide variant comprising amino acids 22-167 of SEQ ID NO:6 in which one or more of amino acids selected from the group consisting of amino acids 52, 55, 70, 84, 88, 91, 94, 97, 109, 117, 120, 121, 125, 126, 127, 128, 131, 138, 156, 158, 162 and 165, according to the numbering of SEQ ID NO: 6, is substituted with a conserved amino acid.

67. (Currently amended) An isolated nucleic acid molecule that encodes an OB polypeptide; capable of modulating body weight; and having one or more polymers attached thereto, said nucleic acid optionally in a pharmaceutically acceptable carrier, wherein said OB polypeptide encoded by said isolated nucleic acid is an OB polypeptide variant comprising amino acid 22-167 of SEQ ID NO:6 in which one or more of amino acids selected from the group consisting of amino acids selected from the group consisting of amino acids 52, 55, 70, 84, 88, 91, 94, 97, 109, 120, 121, 125, 126, 127, 128, 138, 156, 158 and 162, according to the numbering of SEQ ID NO: 6, is substituted with the particular amino acid at the corresponding position in SEQ ID NO: 5.

68. (Cancelled)

69. (Currently amended) The nucleic acid of any one of claims 59 to 67 ~~claim 68~~, wherein at least one of said polymers is a polyamino acid and is N-terminally attached to said OB polypeptide.

70. (Currently amended) The nucleic acid of any one of claims 59 to 67 ~~claim 68~~, wherein at least one of said polymers is a polyamino acid and is C-terminally attached to said OB polypeptide.

71. (Currently amended) The nucleic acid of any one of claims 59 to ~~70~~ 67, wherein said nucleic acid is selected from the group consisting of DNA or RNA.

72. (Currently amended) The nucleic acid of any one of claims 59 to ~~70~~ 67, wherein said nucleic acid is detectably labeled.

73. (Currently amended) A cloning vector comprising a nucleic acid of any one of claims 59 to ~~70~~ 67.

74. (Currently amended) An expression construct comprising a nucleic acid molecule of any one of claims 59 to ~~70~~ 67 operatively associated with an expression control sequence.

75. (Previously added) The expression vector of claim 74, wherein said expression control sequence is selected from the group consisting of cytomegalovirus hCMV immediate early gene, the early or late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC system, the major operator and promoter regions of phage λ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast α -mating factors.

76. (Previously added) A unicellular host transfected with a cloning vector of claim 73.

77. (Previously added) A host cell transformed with an expression construct of claim 74.

78. (Previously added) The host cell of claim 77, wherein said host cell is selected from the group consisting of *E. coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, Pichia yeasts, CHO, R1.1, B-W, L-M, COS-1, COS-7, BSC1, BSC40, BMT10 and cells, plant cells, insect cells and human cells in tissue culture.

79. (Currently amended) A method for preparing an OB polypeptide comprising;

- a) culturing a host cell of claim 76 ~~or 77~~ under conditions that allow the expression of said OB polypeptide; and
- b) recovering the expressed OB polypeptide.

80. (Previously added) The method of claim 79, wherein said host cell is a bacterial cell.

81. (Previously added) The method of claim 79, wherein the host cell is a yeast cell.

82. (Previously added) The method of claim 79, further comprising:

- c) chromatographing the polypeptide on a Ni-chelation column; and
- d) purifying the polypeptide by gel filtration.

83. (Previously added) The method of claim 82, further comprising after step (c) and prior to step (d), chromatographing the OB polypeptide on a strong cation exchanger column.

84. (NEW) A method for preparing an OB polypeptide comprising:

- a) culturing a host cell of claim 77 under conditions that allow the expression of said OB polypeptide; and
- b) recovering the expressed OB polypeptide.

85. (NEW) The method of claim 84, wherein said host cell is a bacterial cell.

86. (NEW) The method of claim 84, wherein the host cell is a yeast cell.
87. (NEW) The method of claim 84, further comprising:
- c) chromatographing the polypeptide on a Ni-chelation column; and
 - d) purifying the polypeptide by gel filtration.
88. (NEW) The method of claim 86, further comprising after step (c) and prior to step (d), chromatographing the OB polypeptide on a strong cation exchanger column.